The status of breast cancer management: Challenges and opportunities

Breast Cancer Research and Treatment

Volumn 75, Issue SUPPL. 1, 2002, Pages

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Chemotherapy; Endocrine therapy; Metastatic; Molecular markers; Primary; Sequencing

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; STEROID RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONFERENCE PAPER; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL;

EID: 0036778136     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1020326219576     Document Type: Conference Paper

References (29)

1. Ovarian ablation in breast cancer: Overview of the randomized trials
2. Chemotherapy with or without oophrectomy in high-risk premenopausal patients with operable breast cancer
3. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial
4. Tamoxifen in the treatment of breast cancer
5. Tamoxifen for early breast cancer: An overview of the randomized trials
6. Zoladex (Goserelin) vs CMF as adjuvant therapy in pre-perimenopausal, node-positive, early breast cancer: Preliminary efficacy results from the zebra study
7. Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer
8. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal (PM) women
9. Polychemotherapy for early breast cancer: An overview of the randomized trials
10. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-postive primary breast cancer (BC)
11. Taxanes in the adjuvant treatment of breast cancer: Why not yet?
12. Neoplasms of the breast
13. Circulating 14er-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
14. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation
15. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
16. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
17. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
18. The evolving role of bisphosphonates
19. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
20. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
21. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
22. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
23. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
24. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
25. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
26. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
27. Gene expression patterns of breast carcinomas distinguish tumor subclass with clinical implications
28. Predicting the clinical status of human breast cancer by using gene expression profiles
29. Gene expression profiles in hereditary breast cancer